Equities analysts forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.25). Oramed Pharmaceuticals reported earnings of ($0.20) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 40%. The firm is expected to report its next quarterly earnings report on Wednesday, December 5th.
On average, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.94). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.14) per share, with EPS estimates ranging from ($1.24) to ($1.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Oramed Pharmaceuticals.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Thursday, July 12th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.03). The company had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $0.61 million. Oramed Pharmaceuticals had a negative return on equity of 63.20% and a negative net margin of 204.00%.
A number of research firms have issued reports on ORMP. ValuEngine cut shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. B. Riley cut shares of Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, July 16th. Finally, HC Wainwright set a $25.00 price target on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday.
NASDAQ ORMP opened at $4.39 on Wednesday. The firm has a market capitalization of $84.56 million, a price-to-earnings ratio of -5.56 and a beta of 0.43. Oramed Pharmaceuticals has a 12-month low of $4.22 and a 12-month high of $11.26.
An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. BlackRock Inc. acquired a new position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 28,041 shares of the biotechnology company’s stock, valued at approximately $209,000. BlackRock Inc. owned 0.16% of Oramed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 1.52% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
Featured Story: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.